These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

234 related articles for article (PubMed ID: 12171721)

  • 1. The CD52 antigen and development of the CAMPATH antibodies.
    Hale G
    Cytotherapy; 2001; 3(3):137-43. PubMed ID: 12171721
    [No Abstract]   [Full Text] [Related]  

  • 2. Pharmacokinetics of CAMPATH-1H in BMT patients.
    Rebello P; Cwynarski K; Varughese M; Eades A; Apperley JF; Hale G
    Cytotherapy; 2001; 3(4):261-7. PubMed ID: 12171714
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Friends, faithfulness and fortunes.
    Hale G
    Cytotherapy; 2001; 3(3):135-6. PubMed ID: 12171720
    [No Abstract]   [Full Text] [Related]  

  • 4. CAMPATH-1 antibodies in stem-cell transplantation.
    Hale G; Cobbold S; Novitzky N; Bunjes D; Willemze R; Prentice HG; Milligan D; MacKinnon S; Waldmann H;
    Cytotherapy; 2001; 3(3):145-64. PubMed ID: 12171722
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rediscovering alemtuzumab: current and emerging therapeutic roles.
    Gribben JG; Hallek M
    Br J Haematol; 2009 Mar; 144(6):818-31. PubMed ID: 19183194
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Alemtuzumab in stem cell transplantation.
    Hale G
    Med Oncol; 2002; 19 Suppl():S33-47. PubMed ID: 12180491
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of in vivo alemtuzumab dose before reduced intensity conditioning and HLA-identical sibling stem cell transplantation: pharmacokinetics, GVHD, and immune reconstitution.
    Chakraverty R; Orti G; Roughton M; Shen J; Fielding A; Kottaridis P; Milligan D; Collin M; Crawley C; Johnson P; Clark A; Parker A; Bloor A; Pettengell R; Snowden J; Pettitt A; Clark R; Hale G; Peggs K; Thomson K; Morris E; Mackinnon S
    Blood; 2010 Oct; 116(16):3080-8. PubMed ID: 20587785
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prevention of graft vs. host disease with alemtuzumab 'in the bag' decreases early toxicity of stem cell transplantation and in multiple myeloma is associated with improved long-term outcome.
    Novitzky N; Thomas V; du Toit C
    Cytotherapy; 2008; 10(1):45-53. PubMed ID: 18202974
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Targeting CD52 as a novel therapeutic strategy in angioimmunoblastic T-cell lymphoma.
    Dunleavy K; Wilson WH
    Leuk Lymphoma; 2010 Sep; 51(9):1583-4. PubMed ID: 20795788
    [No Abstract]   [Full Text] [Related]  

  • 10. Infectious complications following T-cell depleted hematopoietic stem-cell transplantation.
    Novitzky N; Rouskova A
    Cytotherapy; 2001; 3(3):165-73. PubMed ID: 12171723
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Impact on T-cell depletion and CD34+ cell recovery using humanised CD52 monoclonal antibody (CAMPATH-1H) in BM and PSBC collections; comparison with CAMPATH-1M and CAMPATH-1G.
    Williams RJ; Clarke E; Blair A; Evely R; Hale G; Waldmann H; Brookes S; Pamphilon DH
    Cytotherapy; 2000; 2(1):5-14. PubMed ID: 12042050
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T cell depletion of allogeneic stem cell grafts with anti-CD 52 monoclonal antibodies: the Ulm experience from 1983-1999.
    Bunjes D
    Transfus Sci; 2000 Oct; 23(2):151-62. PubMed ID: 11035276
    [No Abstract]   [Full Text] [Related]  

  • 13. Treatment of refractory acute rejection in a lung transplant recipient with campath 1H.
    Reams BD; Davis RD; Curl J; Palmer SM
    Transplantation; 2002 Sep; 74(6):903-4. PubMed ID: 12364881
    [No Abstract]   [Full Text] [Related]  

  • 14. A sialoglycoprotein, gp20, of the human capacitated sperm surface is a homologue of the leukocyte CD52 antigen: analysis of the effect of anti-CD52 monoclonal antibody (CAMPATH-1) on capacitated spermatozoa.
    Focarelli R; Francavilla S; Francavilla F; Della Giovampaola C; Santucci A; Rosati F
    Mol Hum Reprod; 1999 Jan; 5(1):46-51. PubMed ID: 10050661
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential CD52 expression by distinct myeloid dendritic cell subsets: implications for alemtuzumab activity at the level of antigen presentation in allogeneic graft-host interactions in transplantation.
    Ratzinger G; Reagan JL; Heller G; Busam KJ; Young JW
    Blood; 2003 Feb; 101(4):1422-9. PubMed ID: 12393688
    [TBL] [Abstract][Full Text] [Related]  

  • 16. CAMPATH-1H in the treatment of autoimmune cytopenias.
    Marsh JC; Gordon-Smith EC
    Cytotherapy; 2001; 3(3):189-95. PubMed ID: 12171725
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Antimouse CD52 monoclonal antibody inhibits established spontaneous colitis in IL-10-deficient mice.
    Zhu WM; Li Y; Yu C; Li N; Li JS
    Inflamm Bowel Dis; 2011 Jul; 17(7):E72-3. PubMed ID: 21538714
    [No Abstract]   [Full Text] [Related]  

  • 18. Allogeneic stem-cell transplantation for lymphoproliferative disorders using BEAM-CAMPATH (+/- fludarabine) conditioning combined with post-transplant donor-lymphocyte infusion.
    Lush RJ; Haynes AP; Byrne J; Cull GM; Carter GI; Pagliuca A; Parker JE; Mufti G; Mahendra P; Craddock CF; Lui Yin JA; Garg M; Prentice HG; Potter MN; Russell NH
    Cytotherapy; 2001; 3(3):203-10. PubMed ID: 12171727
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Alemtuzumab in the treatment of chronic lymphocytic leukemia.
    Robak T
    BioDrugs; 2005; 19(1):9-22. PubMed ID: 15691213
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
    Kottaridis PD; Milligan DW; Chopra R; Chakraverty RK; Chakrabarti S; Robinson S; Peggs K; Verfuerth S; Pettengell R; Marsh JC; Schey S; Mahendra P; Morgan GJ; Hale G; Waldmann H; Ruiz de Elvira MC; Williams CD; Devereux S; Linch DC; Goldstone AH; MacKinnon S
    Cytotherapy; 2001; 3(3):197-201. PubMed ID: 12171726
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.